TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: GLAXO · data 2026-11-03
GlaxoSmithKline Pharmaceuticals Limited
In plain words
Price: 18.9% below its 52-week high of ₹3,120.7.
Delivery: 57.7% of traded shares were kept for delivery over the last 10 sessions, against 52.5% over the last 60.
Latest results: a net profit of ₹237 cr for the quarter ended Jun 2026 (+15.7% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹3,955 cr |
| Net profit (last 12 months) | ₹1,068 cr |
| Sales growth, 3 years (yearly) | 5.5% |
| Profit growth, 3 years (yearly) | 19.3% |
At a glance
Promoters 75.0% (unchanged in a year), pledged 0.0%, institutions 13.2%.
P/E 40.1, dividend yield 2.3%. Price relative to earnings and book value (low is cheaper, not better).
ROE 49.1%, ROCE 52.8%, operating margin 32.8%: how much profit it earns on the money it uses.
Debt/equity 0.01, Profit growth 19.3% and sales growth 5.5% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (49.1%).
- Healthy operating margin (32.8%).
- Profit grew 19.3% a year over 3 years.
- Pays a dividend yielding 2.3%.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
GLAXO Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹938.44 crore, up 16.6% YoY and down 5.7% QoQ.
Net profit was ₹237.18 crore, up 15.7% YoY and down 14.6% QoQ.
Operating margin was 31.5% (31.2% a year ago).
EPS was ₹14, up 15.7% YoY and down 14.6% QoQ.
GLAXO के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹938.44 करोड़; पिछले साल की तुलना में 16.6% की बढ़त, पिछली तिमाही की तुलना में 5.7% की गिरावट।
शुद्ध मुनाफ़ा: ₹237.18 करोड़; पिछले साल की तुलना में 15.7% की बढ़त, पिछली तिमाही की तुलना में 14.6% की गिरावट।
ऑपरेटिंग मार्जिन: 31.5% (एक साल पहले 31.2%)।
EPS: ₹14; पिछले साल की तुलना में 15.7% की बढ़त, पिछली तिमाही की तुलना में 14.6% की गिरावट।
GLAXOના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹938.44 કરોડ; ગયા વર્ષની સરખામણીએ 16.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 5.7% ઘટાડો.
ચોખ્ખો નફો: ₹237.18 કરોડ; ગયા વર્ષની સરખામણીએ 15.7% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 14.6% ઘટાડો.
ઓપરેટિંગ માર્જિન: 31.5% (એક વર્ષ પહેલાં 31.2%).
EPS: ₹14; ગયા વર્ષની સરખામણીએ 15.7% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 14.6% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
24/100 · Weak over the last ~60 sessions, data 2026-11-02
- Delivery vs usual 4/30: Delivery 51.1% over the last 20 sessions vs 47.7% in the 40 before (1.07x); shares delivered per day 0.37x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 9 schemes hold it, about ₹803 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 8/15: Verdict "Building", sustained score 40/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 3 Aug 26Results Q1 FY27 results: profit +15.7% YoY -0.3% next session
- 29 May 26Dividend Dividend ₹57 (ex-date) -4.0% next session
- 13 May 26Results Q4 FY26 results: profit +5.7% YoY -1.3% next session
- 9 Feb 26Results Q3 FY26 results: profit +28.6% YoY +5.6% next session
- 6 Nov 25Results Q2 FY26 results: profit +2.0% YoY -2.7% next session
- 1 Aug 25Results Q1 FY26 results: profit +12.4% YoY -9.3% next session
- 30 May 25Dividend Dividend ₹42 (ex-date) +0.2% next session
- 13 May 25Results Q4 FY25 results: profit +35.2% YoY +5.8% next session
- 14 Feb 25Results Q3 FY25 results: profit +402.8% YoY +17.1% next session
- 7 Nov 24Dividend Dividend ₹12 (ex-date) -2.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹938 cr | ₹237 cr | +15.7% | 31.5% | 14 |
| Mar 2026 | ₹995 cr | ₹278 cr | +5.7% | 35.3% | 16.4 |
| Dec 2025 | ₹1,041 cr | ₹296 cr | +28.6% | 35.7% | 16.54 |
| Sept 2025 | ₹980 cr | ₹257 cr | +2.0% | 34.3% | 15.07 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% |
| Foreign institutions (FII) | 4.75% | 4.79% | 4.62% | 4.64% |
| Domestic institutions (DII) | 8.48% | 7.80% | 7.68% | 7.70% |
| Mutual funds | 6.07% | 4.87% | 4.73% | 4.77% |
| Retail investors | 9.46% | 10.00% | 10.06% | 10.06% |
| Number of shareholders | 1,19,337 | 1,26,087 | 1,21,763 | 1,22,460 |
Common questions
What was GlaxoSmithKline Pharmaceuticals Limited's latest quarterly profit?
GlaxoSmithKline Pharmaceuticals Limited reported a net profit of ₹237 cr for the quarter ended Jun 2026 (+15.7% on the same quarter a year earlier), on revenue of ₹938 cr.
How much do promoters hold in GlaxoSmithKline Pharmaceuticals Limited?
Promoters held 75.00% of GlaxoSmithKline Pharmaceuticals Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is GlaxoSmithKline Pharmaceuticals Limited debt-free?
Its latest reported debt-to-equity ratio is 0.01, which is very low.
What is GlaxoSmithKline Pharmaceuticals Limited's P/E ratio?
About 40.2, based on the last 12 months' earnings and a price of ₹2,531.4 (data 2026-11-03).
What is the 52-week high and low of GlaxoSmithKline Pharmaceuticals Limited?
The 52-week high is ₹3,120.7 and the 52-week low is ₹2,088.1.
Mutual funds holding GlaxoSmithKline Pharmaceuticals Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 9 schemes holding about ₹803 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Midcap Fund | SBI Mutual Fund | 1.40% | ₹326 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 3.11% | ₹285 cr |
| SBI Dividend Yield Fund | SBI Mutual Fund | 1.55% | ₹125 cr |
| ADITYA BIRLA SUN LIFE MNC FUND | Aditya Birla Sun Life Mutual Fund | 1.57% | ₹48 cr |
| SBI Quant Fund | SBI Mutual Fund | 0.39% | ₹10 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 0.83% | ₹9 cr |
| ADITYA BIRLA SUN LIFE BSE 500 QUALITY 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 0.80% | ₹1 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 0.85% | ₹0 cr |
| Mirae Asset BSE 500 Dividend Leaders 50 ETF | Mirae Asset Mutual Fund | 0.51% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Limited | ₹2,531.4 | ₹42,073 cr | 40.2 | — | 49.1% | 52.8% | 0.01 | -3.8% |
| Gland Pharma Ltd. | ₹3,066.6 | ₹51,112 cr | 44.8 | — | 10.5% | 12% | 0.03 | +59.8% |
| IPCA Laboratories Limited | ₹1,949.9 | ₹48,898 cr | 37.8 | — | 15.2% | 16.3% | 0.1 | +50.5% |
| Ajanta Pharma Limited | ₹3,396.3 | ₹43,891 cr | 33.6 | 8.7 | 25.4% | 30% | 0.06 | +37.6% |
| Emcure Pharmaceuticals Limited | ₹1,883.5 | ₹35,440 cr | 35.3 | — | 19.7% | 22.6% | 0.31 | +41.6% |
| Acutaas Chemicals Ltd | ₹3,892.6 | ₹32,770 cr | 72.9 | 17.2 | 24% | 28.9% | 0.02 | +128.5% |
Compare GLAXO with GLAND in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open GLAXO in TickerKhoj →